I don't know the numbers but if it's anything like T315i and CML then this wouldn't provide much of a market opportunity, small numbers of patients.
I would think refractory, resistant (gatekeeper or otherwise), intolerant, all comers trial. Similar to the ponatanib design. But perhaps others have different opinions.
Unless it's too early and they don't want to comment, hopefully Ariad will discuss possible regulatory strategies at their upcoming analyst day.
Post approval, if they get there, a head to head study for front line.
News 
Market Data 
Discover 
